DnB Asset Management
CHRS icon

DnB Asset Management’s Coherus Oncology CHRS Stock Holding History

DnB Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18,290
Closed -$294K – 670
2021
Q3 		$294K Sell
18,290
-4,363
-19% -$64K ﹤0.01% 633
2021
Q2 		$313K Buy
22,653
+2,368
+12% +$33.5K ﹤0.01% 622
2021
Q1 		$296K Sell
20,285
-742
-4% -$12.6K ﹤0.01% 629
2020
Q4 		$365K Buy
21,027
+1,584
+8% +$28.2K ﹤0.01% 612
2020
Q3 		$357K Buy
19,443
+1,626
+9% +$30.2K ﹤0.01% 598
2020
Q2 		$318K Buy
+17,817
New +$302K ﹤0.01% 591

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DnB Asset Management's CHRS Position: Q4 2021 in Review

DnB Asset Management sold out of Coherus Oncology (CHRS) in Q4 2021, closing a stake of 18,290 shares — an estimated $294K sold.

DnB Asset Management first reported a position in CHRS in Q2 2020 and held it in 6 quarters. The position peaked at $365K in Q4 2020. 201 funds tracked by Wall St. Rank hold CHRS as of Q4 2021.

  • DnB Asset Management reported no remaining Coherus Oncology position as of Q4 2021 after selling out during the quarter.
  • DnB Asset Management sold 18,290 Coherus Oncology shares in Q4 2021, an estimated $294K.
  • DnB Asset Management first reported a position in Coherus Oncology in Q2 2020 and held it in 6 quarters.
  • DnB Asset Management's Coherus Oncology position peaked at $365K in Q4 2020.
  • 201 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2021.

Based on DnB Asset Management's 13F filing for Q4 2021, filed 12 Jan 2022.